Daily Stock Analysis, CDNA, CareDx Inc, priceseries

CareDx Inc. Daily Stock Analysis
Stock Information
Open
31.53
Close
31.72
High
32.09
Low
31.26
Previous Close
37.40
Daily Price Gain
-5.68
YTD High
41.27
YTD High Date
Jul 11, 2019
YTD Low
21.46
YTD Low Date
Jan 7, 2019
YTD Price Change
7.74
YTD Gain
32.28%
52 Week High
41.27
52 Week High Date
Jul 11, 2019
52 Week Low
11.93
52 Week Low Date
Jul 30, 2018
52 Week Price Change
19.23
52 Week Gain
153.96%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 4. 2017
1.18
May 5. 2017
1.27
1 Trading Days
8.05%
Link
LONG
Aug 11. 2017
1.55
Sep 5. 2017
2.66
16 Trading Days
71.83%
Link
LONG
Sep 21. 2017
2.97
Oct 23. 2017
5.64
22 Trading Days
89.80%
Link
LONG
Nov 17. 2017
5.96
Dec 4. 2017
6.90
10 Trading Days
15.73%
Link
LONG
Apr 3. 2018
8.00
May 14. 2018
10.66
29 Trading Days
33.24%
Link
LONG
May 30. 2018
12.49
Jun 19. 2018
14.77
14 Trading Days
18.25%
Link
LONG
Jul 31. 2018
13.46
Sep 12. 2018
23.69
30 Trading Days
76.03%
Link
LONG
Oct 30. 2018
24.55
Nov 9. 2018
25.89
8 Trading Days
5.47%
Link
LONG
Jan 18. 2019
24.62
Feb 1. 2019
26.74
9 Trading Days
8.59%
Link
LONG
Feb 20. 2019
26.87
Mar 27. 2019
35.71
25 Trading Days
32.91%
Link
LONG
May 8. 2019
29.15
May 23. 2019
31.79
11 Trading Days
9.05%
Link
LONG
Jun 3. 2019
32.80
Jun 21. 2019
36.74
14 Trading Days
12.01%
Link
Company Information
Stock Symbol
CDNA
Exchange
NasdaqGM
Company URL
http://www.caredxinc.com
Company Phone
415-287-2300
CEO
Peter K. Maag
Headquarters
California
Business Address
3260 BAYSHORE BOULEVARD, BRISBANE, CA 94005
Sector
Equity
Industry Category
Diversified Services
Industry Group
Research Services
CIK
0001217234
About

CareDx, Inc. operates as a commercial stage company, which engages in developing, marketing, and delivering a diagnostic surveillance solution. Its product includes AlloMap, which aids clinicians in identifying heart transplant recipients with stable allograft function. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Description

CareDx, Inc., a molecular diagnostics company, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in the United States and internationally. The company's commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. It is also developing AlloSure, a next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.